Abstract: A pyrazolopyrimidine derivative of the formula [I] wherein R1 is an optionally substituted aromatic ring group, an optionally substituted lower alkyl group or an optionally substituted amino group; R2 is an optionally substituted aromatic ring group; R3 is an optionally substituted lower alkyl group; and R4 is a hydrogen atom, a lower alkyl group, a halogen atom, a nitro group or an amino group; or a pharmaceutically acceptable salt thereof is useful as an antagonist of CRF receptor.

Abstract: Disclosed is a pyridazinone compound represented by the formula (I): ##STR1## wherein X represents hydrogen atom or the like; Y represents a single bonding arm, oxygen atom or sulfur atom; A represents a straight or branched alkylene group which may have a double bond;B represents carbonyl group or thiocarbonyl group; and R.sup.2 represents an alkyl group having 1 to 10 carbon atoms which may be substituted or the like; orB represents sulfonyl group; and R.sup.2 represents a lower alkenyl group or the like;R.sup.1 represents hydrogen atom or the like; R.sup.3 represents hydrogen atom or the like; R.sup.4 represents hydrogen atom or the like; and R.sup.5 represents hydrogen atom or the like,or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a pyridazinone compound represented by the formula (I): ##STR1## wherein X represents hydrogen atom or the like; Y represents a single bonding arm, oxygen atom or sulfur atom; A represents a straight or branched alkylene group which may have a double bond;B represents carbonyl group or thiocarbonyl group; and R.sup.2 represents an alkyl group having 1 to 10 carbon atoms which may be substituted or the like; orB represents sulfonyl group; and R.sup.2 represents a lower alkenyl group or the like;R.sup.1 represents hydrogen atom or the like; R.sup.3 represents hydrogen atom or the like; R.sup.4 represents hydrogen atom or the like; and R.sup.5 represents hydrogen atom or the like,or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are an indane compound represented by the formula: ##STR1## wherein R.sup.1 represents a lower alkyl group, a lower alkenyl group or a substituted or unsubstituted mono-cyclic aromatic heterocyclic group having nitrogen atom as a hetero atom; R.sup.2 represents hydrogen atom or a lower alkyl group; and A represents a lower alkylene group,or a pharmaceutically acceptable salt thereof and processes for preparing the same.

Abstract: Disclosed are an indane compound represented by the formula: ##STR1## wherein R.sup.1 is aryl, lower alkyl, cycloalkyl, halogeno-lower alkyl, lower alkenyl, phenyl-substituted lower alkenyl, monocyclic or bicyclic aromatic heterocyclic having N, O or S as a hetero atom, lower alkoxy, phenoxy, lower alkylamino, lower alkenylamino, phenyl-amino, lower alkyl substituted by monocyclic or bicyclic aromatic heterocyclic having N, O or S as a hetero atom, or lower alkenyloxy; R.sup.2 is H or lower alkyl; X is carbonyl or thiocarbonyl; Alk is single bonding arm or lower alkylene; and the dotted line is presence or absence of a double bond, or a pharmaceutically acceptable salt thereof, processes for preparing the same and a synthetic intermediate thereof.

Abstract: Disclosed are indane compounds represented by the formula: ##STR1## wherein R.sup.1 is aryl, lower alkyl, cycloalkyl, halogeno-lower alkyl, lower alkenyl, phenyl-substituted lower alkenyl, monocyclic or bicyclic aromatic heterocyclic having N, O or S as a hetero atom, lower alkoxy, phenoxy, lower alkylamino, lower alkenylamino, phenylamino, lower alkyl substituted by monocyclic or bicyclic aromatic heterocyclic having N, O or S as a hetero atom, or lower alkenyloxy; R.sup.2 is H or lower alkyl; X is carbonyl or thiocarbonyl; Alk is single bonding arm or lower alkylene; and the dotted line is presence or absence of a double bond, for treating endotoxin shock and/or nephritis.